Amrubicin Hydrochloride

盐酸氨柔比星

Report date: 2023/03/20 14:39:06
NME

Base Information

Drug NameAmrubicin Hydrochloride
Drug Alias Name盐酸氨比柔星AmrubicinumAmrubicine氨柔比星Amrubicina +[10] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > Anthracycline antibioticsSmall molecules > Heterocyclic drugs > Antibiotics
Mechanisms of ActionTopoisomerase II inhibitors
TargetsTopoisomerase II
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursSmall Cell Lung Carcinoma +[6] 
Global Approved IndicationsSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2002/04/11
Country/TerritoryUnited StatesNetherlandsUnited Kingdom +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPending
Originator CompaniesSumitomo Dainippon Pharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDainippon Sumitomo Pharma Co Ltd
Inactive CompaniesUtah State UniversityCelgene CorpSumitomo Pharmaceuticals Co Ltd +[5] 
Active IndicationsSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung
Inactive IndicationsMetastatic breast cancerSolid tumoursLung Neoplasms +[4] 

Other Information

ATC CodeL01DB10
Related LinksWikipediaDrugBankKEGG